Teva Pharmaceutical Industries (NYSE:TEVA) Sees Unusual Trading Volume in Its Shares

Teva Pharmaceutical on the Street Analysts’ Recommendations in September

The Pdt Partners Llc holds 12,543 shares with $96,000 value, down from 137,000 last quarter.

The company has lost market value and investor confidence in the months-long search for a new top executive who would come up with a plan to address Teva's challenges in its US generic drug business and large debt from the $40 billion acquisition of Allergan's generics business in 2015. The stock rose 11.10% or $1.72 reaching $17.22 per share. About 52.34 million shares traded or 70.43% up from the average. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has declined 41.70% since September 12, 2016 and is downtrending. It has underperformed by 58.40% the S&P500.The move comes after 5 months positive chart setup for the $18.94B company. The sales growth rate for a stock is a measure of how the stock's sales per share (SPS) has grown over a specific period of time. The company reported $0.99 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $1.06 by $0.07.

The company's consensus rating on Reuter's scale remained unchanged from 2.75 to 2.75 during a month. Blackrock Advisors Ltd invested in 122,204 shares or 0% of the stock. About 322,549 shares traded.

Airain Ltd increased Teva Pharmaceutical Adr (TEVA) stake by 7.42% reported in 2016Q4 SEC filing. Five equities research analysts have rated the stock with a sell rating, nineteen have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. Teva Pharma has $86 highest and $14 lowest target. TEVA's previous stock rating was a Neutral.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings data on Monday, February 13th. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) earned "Outperform" rating by Oppenheimer on Thursday, July 14. The rating was upgraded by BTIG Research to "Buy" on Monday, September 11. Sharkey Howes & Javer now owns 2,008 shares of the company's stock valued at $101,000 after buying an additional 358 shares in the last quarter. (NASDAQ:LSTR) rating on Friday, October 23. Raymond James Financial Svcs Advsrs holds 20,292 shares or 0% of its portfolio. It also reduced its holding in Fidelity Natl Information Sv (NYSE:FIS) by 4,657 shares in the quarter, leaving it with 43,503 shares, and cut its stake in Horizon Pharma Plc (NASDAQ:HZNP). Jefferies Group LLC reissued a "hold" rating and set a $26.00 price target (down from $33.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Its down 0.06, from 0.86 in 2016Q3. 47 funds opened positions while 63 raised stakes. Blackrock Institutional Na stated it has 80,267 shares or 0% of all its holdings. Washington Tru Bancorp holds 92 shares. Bancorporation Of New York Mellon Corp reported 0.01% stake. Banc Funds Co Llc owns 36,941 shares or 0.06% of their USA portfolio. Cwm Lc stated it has 652 shares. M&T Comml Bank Corporation accumulated 28,509 shares. Alliancebernstein Limited Partnership owns 724,639 shares.

"At Lundbeck, it was a troubled company and he turned it around and created significant value for shareholders". On Tuesday, September 13 the stock rating was initiated by Atlantic Securities with "Overweight". Therefore 21% are positive. MFA Mortgage had 12 analyst reports since January 15, 2016 according to SRatingsIntel. The firm has "Hold" rating given on Friday, August 4 by Maxim Group. Vetr upgraded Rite Aid Corporation (NYSE:RAD) rating on Wednesday, August 19. As per Tuesday, August 22, the company rating was maintained by KeyBanc Capital Markets. They now have a Dollars 26 price target on the stock. They now have a United States dollars 30 price target on the stock. The brokerage now has an underperform rating on the stock. The firm has "Hold" rating given on Monday, August 28 by Cowen & Co. RBC Capital Markets has "Sector Perform" rating and $66 target.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.